To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Iron Complex with a Killer Instinct
Iron-containing nucleoside analogs kill tumor cells - organometallic compounds as a new class of drugs
03-24-2004: German researchers have successfully developed a new class of cytostatics that
drive cancer cells to programmed suicide (apoptosis): iron-containing nucleoside
analogs. With their discovery, the team led by Hans-Günther Schmalz (University
of Cologne), Thomas Wieder (University of Tübingen), and Aram Prokop (Charité,
Berlin) has opened a new chapter in bio-organometallic chemistry.
Phosphate-bridged nucleosides are the building blocks that make up our nucleic
acids (DNA and RNA), carriers of genetic information. In addition, nucleosides,
again linked through one or more phosphate groups, also perform other important
tasks, such as energy delivery (adenosine triphosphate, ATP) or as a messenger
in signal transmission within cells. Nucleoside analogs, such as the nucleoside
antibiotics Carbovir and Tubercidine, are established drugs for fighting
viruses, bacteria, and fungi, as well as being cytostatics. Analogs of natural
metabolites are under consideration as drugs because they so closely resemble
their "models" in structure that they compete with them, inhibiting or
misdirecting physiological processes.
Nucleosides are made of one of the nucleotide bases, adenine, cytosine, guanine,
and thymine (DNA) or uracil (RNA), bound to a ribose unit. Ribose is a
ring-shaped sugar made of five carbon atoms. From previous work, the chemists
knew that a specific type of ribose analog can be highly selectively coupled to
the right location on a nucleotide base if the ribose analog is bound to an
iron-carbonyl complex. The complex stabilizes an intermediate product in the
reaction. A carbonyl complex is a coordination complex in which the central
metal atom surrounds itself with carbon monoxide molecules (CO) as ligands.
Using this technique, the researchers produced a kaleidoscope of different
nucleoside analogs. Instead of removing the metal complex after the reaction,
however, they decided to test the pharmacological potential of the
iron-containing nucleoside analogs. The result: several of the complex-bound
nucleoside analogs proved to be distinctly cytotoxic toward tumor cells and
degenerate lymphoblasts of the type found in children with acute leukemia.
Compounds of the nucleotide base cytosine were especially effective. In
contrast, a decomplexed version proved to be considerably less active. "The
metal carbonyl fragment is clearly important to the biological activity," says
Schmalz, "we are currently researching the precise implications. We are also
working on compounds with an improved pharmacological profile."
Watchlist
This is where you can add this news to your personal favourites
- 1Arkema speeds up its development in Asia and in green chemistry with the closing of the acquisition of Hipro Polymers and Casda Biomaterials
- 2BASF increases prices for ethanolamines in Europe
- 3LANXESS expands Jhagadia site to serve booming Indian market
- 4Bayer CO2 project among best ideas for the future
- 5Rhodia and Avantium to jointly develop biobased polyamides
- 6From seaweed to biofuels
- 7Bayer rated the most sustainable German company in its sector
- 8How seawater could corrode nuclear fuel
- 9Largest and most efficient BOPP line for Africa
- 10DEKRA: Change in management of Business Unit Industrial
- 1Baytron P®– Gateway to a new generation of polymers
- 2Rhodia and Avantium to jointly develop biobased polyamides
- 3Solvay acquires Alexandria Sodium Carbonate company in Egypt
- 4REACH Candidate List of Substances of Very High Concern for Authorisation Grows
- 5AkzoNobel selects Tebodin for the conversion of the chlorine plant in Frankfurt
- 6AkzoNobel doubles dimethylether production
- 7Are you certain, Mr. Heisenberg?
- 8BASF invests $50 million to acquire equity ownership position in Sion Power
- 9Bayer MaterialScience commissions new hydrogenation technical center
- 10Illinois Tool Works Inc. acquires AppliChem GmbH
- 1Evonik Industries’ Coatings & Additives announces price increases
- 2Solvay acquires Alexandria Sodium Carbonate company in Egypt
- 3Baytron P®– Gateway to a new generation of polymers
- 4REACH Candidate List of Substances of Very High Concern for Authorisation Grows
- 5Drew Industrial Division of Ashland Specialty Chemical Company purchases industrial water-treatment business of London-based Fer
- 6Electrochemical extraction of silicon: new approach for a more environmentally friendly large-scale process?
- 7LG-DOW Polycarbonate Plant Starts Production in Korea to Effectively Meet Regional Needs
- 8Caflon® surfactants from Univar as substitutes for banned nonylphenol ethoxylates
- 9Largest and most efficient BOPP line for Africa
- 10New Fluka and Riedel-de Haën Catalog Features Over 1,500 New Products
- Heraeus launches cooperation with top-tier Chinese university -
- Millipore Corporation to Acquire Serologicals -
- Cognis and Golden Hope agree to expand oleochemicals joint venture -
- Rhodia Organics increases prices for its vanillin and ethylvanillin range -
- Air Products and Technip Extend Global Alliance -
